For the Inventor, By the Inventor

Enter assignee name

Gaithersburg, MD, United States of America

Lentigen Technology, Inc.

USPTO Granted Patents = 40

EPO Patents = 9

Forward Citations = 66

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Dina Schneider (40 out of 41 patents)

Boro Dropulic (38 out of 50 patents)

Rimas J Orentas (34 out of 46 patents)

4. Zhongyu Zhu (20 out of 54 patents)

5. Dimiter Stanchev Dimitrov (17 out of 102 patents)

6. Stefan Miltenyi (5 out of 65 patents)

7. Peirong Hu (5 out of 5 patents)

8. Waleed M Haso (5 out of 5 patents)

9. Bang Khoa Vu (2 out of 2 patents)

10. Leah Marie Alabanza (2 out of 2 patents)

11. Kim Anthony Gonda (2 out of 2 patents)

12. Winfried Krueger (2 out of 2 patents)

13. Florian Tomszak (1 out of 1 patent)

14. Rafijul Bari (1 out of 1 patent)

15. Terry J Fry (1 out of 5 patents)

Core Competencies:

Anti-CD33

Anti-CD19

DuoCARs

Chimeric Antigen Receptors

Anti-BCMA

Anti-CD38

Self-Driving CARs

Engineered T-Cells

Anti-Mesothelin

HIV/AIDS Treatment

Anti-CD22

Anti-ROR1

40 patents: Sort by Forward Citations

1. 12714750 - Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy (2026-08-25),

2. 12624104 - Compositions and Methods for Treating Cancer with Anti-CD19 Immunotherapy (2026-05-12),

3. 12465641 - Chimeric Antigen Receptor Therapies for Treating Solid Tumors (2025-11-11),

4. 12391958 - Compositions and methods for treating cancer with anti-CD38 immunotherapy (2025-08-19),

5. 12391740 - Compositions and methods for treating cancer with anti-BCMA immunotherapy (2025-08-19),

6. 12371490 - Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy (2025-07-29),

7. 12365718 - Compositions and methods for treating cancer with DuoCARs (2025-07-22),

8. 12193995 - Method to treat cancer with engineered T-cells (2025-01-14),

9. 12122831 - Compositions and methods for treating cancer with anti-CD19/CD22 immunotherapy (2024-10-22),

10. 12037403 - Compositions and methods for treating cancer with anti-CD123 immunotherapy (2024-07-16),

11. 12024554 - Compositions and methods for treating HIV/AIDS with immunotherapy (2024-07-02),

12. 11970528 - Compositions and methods for treating cancer with anti-mesothelin immunotherapy (2024-04-30),

13. 11969443 - Compositions and methods for treating cancer with self-driving chimeric antigen receptors (2024-04-30),

14. 11905515 - Chimeric antigen receptors and methods of use (2024-02-20),

15. 11878052 - Compositions and methods for treating cancer with anti-CD22 immunotherapy (2024-01-23),

Company Overview

Lentigen Technology, Inc. is a biotechnology company based in Gaithersburg, Maryland, specializing in the development and manufacturing of lentiviral vector systems. These systems are pivotal for gene therapy applications, enabling the delivery of genetic material into cells for therapeutic purposes. The company focuses on advancing innovative solutions for the treatment of various diseases, including genetic disorders and cancers, by leveraging its expertise in viral vector technology and cell engineering.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

40 Patents

#10 in Gaithersburg, MD

#101 in Maryland

#8,635 in US

#17,087 in the World

Gaithersburg, MD, United States of America

Lentigen Technology, Inc.

Forward Citations = 66

19 inventors:

Dina Schneider (40 out of 41 patents)

Boro Dropulic (38 out of 50 patents)

Rimas J Orentas (34 out of 46 patents)

4. Zhongyu Zhu (20 out of 54 patents)

5. Dimiter Stanchev Dimitrov (17 out of 102 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Lentigen Technology, Inc.. Retrieved from https://idiyas.com/company/lentigen-technology

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…